135 related articles for article (PubMed ID: 37721227)
1. Baseline glycated hemoglobin and potassium level correlated with pretreatment QT-corrected interval among patients with diabetic drug-resistant tuberculosis.
Putra ON; Yulistiani Y; Soedarsono S; Subay S
Int J Mycobacteriol; 2023; 12(3):241-247. PubMed ID: 37721227
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
Liu F; Gao J; Gao M; Liu Y; Shu W; Xie L; Sun Y; Zhang L; Li L; Pang Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0203321. PubMed ID: 36047781
[TBL] [Abstract][Full Text] [Related]
4. Relationship between electrolytes and glycated hemoglobin among diabetic patients with poor adherence to antidiabetic medications: a cross-sectional study.
Lengeiya F; Mathenge S; Ojola P
Pan Afr Med J; 2024; 47():37. PubMed ID: 38586073
[TBL] [Abstract][Full Text] [Related]
5. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation.
Jin Y; Benkeser D; Kipiani M; Maranchick NF; Mikiashvili L; Barbakadze K; Avaliani Z; Alghamdi WA; Alshaer MH; Peloquin CA; Blumberg HM; Kempker RR
Int J Antimicrob Agents; 2023 Oct; 62(4):106939. PubMed ID: 37517627
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Moxifloxacin Concentration, C-Reactive Protein, and Inflammatory Cytokines on QTc Interval in Rifampicin-Resistant Tuberculosis Patients Treated with Shorter Regimens.
Kusmiati T; Mertaniasih NM; Putranto JNE; Suprapti B; Luthfah N; Soedarsono S; Koesoemoprodjo W; Sari AP
Acta Med Indones; 2022 Jan; 54(1):19-27. PubMed ID: 35398822
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis.
Li J; Yang G; Cai Q; Wang Y; Xu Y; Zhang R; Lang Y; Cai X
Int J Infect Dis; 2021 Sep; 110():179-186. PubMed ID: 34293490
[TBL] [Abstract][Full Text] [Related]
8. Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis.
Putra ON; Yulistiani Y; Soedarsono S
Int J Mycobacteriol; 2022; 11(4):349-355. PubMed ID: 36510917
[TBL] [Abstract][Full Text] [Related]
9. Correlation of inflammatory cytokines on corrected QT interval in rifampicin-resistant tuberculosis patients.
Kusmiati T; Mertaniasih NM; Eko Putranto JN; Suprapti B; Soedarsono ; Luthfah N; Koesoemoprodjo W; Sari AP
Ann Med Surg (Lond); 2021 Oct; 70():102862. PubMed ID: 34584687
[TBL] [Abstract][Full Text] [Related]
10. Comparison of QTc interval changes in drug-resistant tuberculosis patients on delamanid-containing regimens versus shorter treatment regimens.
Jefman Efendi Marzuki HY; Nafrialdi N; Sawitri N; Sugiri YJ; Gusti Agung Ayu Putu Sri Darmayani I; Ascobat P
Int J Risk Saf Med; 2024; 35(2):181-190. PubMed ID: 38701163
[TBL] [Abstract][Full Text] [Related]
11. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
[TBL] [Abstract][Full Text] [Related]
12. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
Barvaliya SV; Desai MK; Panchal JR; Solanki RN
Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
[TBL] [Abstract][Full Text] [Related]
13. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens.
Kusmiati T; Made Mertaniasih N; Nugroho Eko Putranto J; Suprapti B; Luthfah N; Soedarsono S; Koesoemoprodjo W; Prawita Sari A
J Clin Tuberc Other Mycobact Dis; 2022 Aug; 28():100320. PubMed ID: 35706565
[TBL] [Abstract][Full Text] [Related]
15. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
Olayanju O; Esmail A; Limberis J; Dheda K
Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
[TBL] [Abstract][Full Text] [Related]
16. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
Gao JT; Du J; Wu GH; Pei Y; Gao MQ; Martinez L; Fan L; Chen W; Xie L; Chen Y; Wang H; Jin L; Li GB; Zong PL; Xiong Y; Wu QH; Li MW; Yan XF; Miao YF; Cai QS; Li XJ; Bai DP; Geng SJ; Yang GL; Tang PJ; Zeng Y; Chen XH; Li TX; Cai C; Zhou Y; Zhuo M; Wang JY; Guan WL; Xu L; Shi JC; Shu W; Cheng LL; Teng F; Ning YJ; Xie SH; Sun YX; Zhang LJ; Liu YH
Infect Dis Poverty; 2021 Mar; 10(1):32. PubMed ID: 33736710
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis.
Putra ON; Yulistiani Y; Soedarsono S; Subay S
Perspect Clin Res; 2024; 15(2):89-93. PubMed ID: 38765544
[TBL] [Abstract][Full Text] [Related]
19. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
[TBL] [Abstract][Full Text] [Related]
20. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study.
Shi L; Gao J; Gao M; Deng P; Chen S; He M; Feng W; Yang X; Huang Y; He F; Hu Y; Lei L; Li X; Du J; Hu X; Liu Z; Tang P; Han J; Wang H; Han Y; Shu W; Sun Y; Pei Y; Liu Y
Infect Dis Ther; 2021 Mar; 10(1):457-470. PubMed ID: 33515206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
